UP-57 Randomized Controlled Trial Comparing Holmium Laser Xpeeda Vaporesection and GreenLight XPS Vaporization of the Prostate: 6 months follow up
Thursday June 27, 2019 from

Hazem M. Elmansy, Canada

Assistant Professor




Randomized controlled trial comparing holmium laser Xpeeda Vaporesection and GreenLight XPS Vaporization of the prostate: 6 months follow up

Waleed Shabana1, Abdulrhman Ahmed1, Fabiola Oquendo1, Amr Hodhod1, Rayan Kelly1, Shalyn Littlefield1, Ahmed Kotb1, Walid Shahrour1, Hazem Elmansy1.

1Northern Ontario School of Medicine, Thunder Bay, ON, Canada

Introduction: To compare the safety and efficacy of Holmium Laser XpeedaTM Vaporesection and GreenLight XPSTM Vaporization of the Prostate in patients with prostate glands ≤80 g.

Methods: Eighty men with benign prostatic hyperplasia (BPH) and prostate glands ≤80 g scheduled for laser prostatectomy were included in this prospective randomized trial. Outcome measures including IPSS, QoL, flow rate, PVR, IIEF-15, ICIQ-SF, PSA, catheterization time, and TRUS prostate volume changes were collected and compared. Perioperative complications were also recorded. Patients were offered a trial of void (TOV) 3 hours after their procedures. All patients were discharged home on the same day and were followed up at 1, 3, and 6 months.

Results: There were no significant differences in preoperative baseline data between the two surgical groups. Successful TOV was noted in 70.5% and 70.8% of the XpeedaTM and GreenLight XPSTM patients, respectively p=0.5. The laser energy used was significantly lower in XpeedaTM group p=0.002. There were no significant differences in functional and sexual outcomes between both groups at 6 months. Operative parameters and postoperative outcomes are shown in Table 1.

Conclusions: Holmium Laser Xpeeda™ Vaporesection and GreenLight XPSTM Vaporization are safe and effective in the treatment of BPH. Same-day discharge with early trial of void is a feasible option.

© 2022 CUA 74th Annual Meeting